Aldara for the Treatment of Extensive Alopecia Areata
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00177021
Recruitment Status :
First Posted : September 15, 2005
Last Update Posted : November 13, 2006
Hordinsky, Maria K., MD
National Alopecia Areata Foundation
Information provided by:
University of Minnesota - Clinical and Translational Science Institute
We propose to examine the efficacy and tolerability of Aldara Cream 5% for the treatment of extensive alopecia areata. Aldara is a immune-response modifier. The drug induces the production of cytokines which are small, hormone-like proteins involved in cellular communication during immune responses. We hypothesize that this drug will effect the inflammatory cells present around hair follicles in patients with alopecia areata.
Condition or disease
Drug: Aldara Cream 5%
Ten patients with extensive scalp alopecia areata (>95% hair loss)of less than 2 years duration will be invited to participate in this study. For six months each person will be asked to apply Aldara Cream 5% daily to the right half of the scalp. No drug will be applied to the left side. Skin biopsies will be taken of the right scalp before and at the completion of the therapy.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Must give written informed consent.
Must be 18 years of age, male or female of any race.
Subjects must have extensive scalp alopecia areata (>95% involvement) of less than 2 years duration.
In good general and mental health based on a medical history and physical exam.
Patient must be willing to refrain from all other alopecia areata treatments during the course of the study.
Must agree to shampoo daily with Free and Clear shampoo.
History of any illness or condition that in the opinion of the investigator might confound the results of the study or pose additional risk in administering the drug to the patient.
Significant abnormalities on screening clinical examination.
Previous use of Aldara Cream 5%
History of drug or alcohol abuse.
Use of ultraviolet radiation, including tanning beds and PUVA therapy for treatment of acne, psoriasis, or any other skin condition within 2 months prior to study initiation.
Use of systemic or topical glucocorticoids, corticosteroids. estrogenic, progestogenic, androgenic, or antiandrogen drugs, cyclosporine, FK506 or immunotherapy with DNCB, SADBE, or DCP within 6 months of study initiation.
Use of a topical medication within six weeks prior to the study.
Alterations in thyroid medication within 6 months of study initiation.